Delivery Order SPE2DB22D3401-SPE2DB25FT6GH
- Not listed
- The Defense Logistics Agency (DLA) awarded a $11,458.33 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on June 13, 2025, with an ultimate completion date of June 16, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dupixent 300 mg/2 ml pen injections (2 ml quantity) with a ceiling value of $21,486.82. This is a firm fixed price delivery order issued under a non-competitive, non-set-aside procurement. The order is set for ultimate completion by September 11, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,797.68 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on June 4, 2025, with completion scheduled for June 5, 2025. This non-set-aside, firm fixed-price delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a $16,998.05 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with completion scheduled for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery is scheduled to occur at AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,721.25 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on September 5, 2025, with a completion date of September 8, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under a larger indefinite delivery contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $25,982.33 on August 21, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,527.14 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 7, 2025, with completion targeted for August 8, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award executed under the company's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be supplied from the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $34,724.93 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $12,949.95 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units). This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-set-aside award. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a $38,968.29 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors. This is a firm fixed price, non-set-aside delivery order with performance through September 5, 2025, and fulfillment from the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop...
- SPE2DB22D3401Indefinite Delivery Contract
- SPE2DB22D3401-SPE2DB25FT6GHDelivery Order
The Defense Logistics Agency (DLA) awarded a $109,423.55 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on September 17, 2025, with an ultimate completion date of September 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999 and running through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, leverages its IDC with the DLA to supply a broad range of medications and medical supplies to support military healthcare programs worldwide. This specific delivery order for Dupixent—a biologic medication used for conditions including atopic dermatitis and eosinophilic conditions—exemplifies the company's role in providing specialty pharmaceuticals to federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard. The firm fixed price structure and rapid completion timeline reflect the efficient procurement model established under the DLA's pharmaceutical prime vendor agreements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $109.4k | 9/17/25 |